Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial

Pharmacopsychiatry

Volumn 41, Issue 1, 2008, Pages 24-28

  Assion, H J ^a   Reinbold, H ^b   Lemanski, S ^c   Basilowski, M ^a   Juckel, G ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b LWL Klinik Dortmund   (Germany)

^c Child and Adolescent Psychiatry   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; PLACEBO;

ADULT; AGED; AKATHISIA; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TREMOR;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG SYNERGISM; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SCHIZOPHRENIA; SULPIRIDE;

EID: 38849155770     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993209     Document Type: Article

References (40)

1. Agelink M, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004; 161: 924-925
2. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005; 66: 63-72
3. Bergemann N, Kress KR, Frick A, Kopitz J. Amisulpride has no effect on plasma clozapine concentrations. J Clin Psychopharmacol 2005; 25: 494-498
4. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995; 21: 579-591
5. Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol 2006, (Epub ahead of print)
6. Cook B, Hoogenboom G. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia. Australasian Psychiatry 2004; 12: 74-76
7. Croissant B, Hermann D, Olbrich R. Reduction of side effects by combining clozapine with amisulpride: Case report and short review of clozapine-induced hypersaiivation. Pharmacopsychiatry 2005; 38: 38-39
8. Demling JH, Huang ML, Remmerie B et al. Pharmacokinetics and safety of combination therapy with lithium and risperidone. Pharmacopsychiatry 2006; 39: 230-231
9. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods 2007; 39: 175-191
10. Flynn SW, MacEwan GW, Altman S, Kopala LC et al. An open label comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 1998; 31: 25-29
11. Freudenreich O, Henderson DC, Walsh JP et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007; 92: 90-94
12. Gaebel W, Falkai P. Behandlungsleitlinie Schizophrenie. Reihe S3 Praxisleitlinien in Psychiatrie und Psychotherapie, Band 1. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (Hrsg.). Darmstadt, Steinkopff, 2006
13. Genc Y, Taner E, Candansayar S. Comparison of clozapine- amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 2007; 24: 1-13
14. George S, Cowan C. Effectiveness of amisulpride augmentation of clozapine in a non-responder to either drug alone: a case-report. Acta Psychiatr Scand 2005; 111: 163
15. Honer WG, Thornton AE, Chen EY et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472-482
16. Josiassen RC, Joseph A, Kohegyi E et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatr 2005; 163: 130-136
17. Kaempf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: A promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005; 38: 39-40
18. Kapur S, Roy P, Daskalakis J et al. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001; 158: 311-314
19. Kivircik Akdede BB, Anil Yagcioglu AE, Alptekin K et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 2006; 67: 1912-1919
20. Lerner V, Bergmann J, Borokhov A et al. Augmentation of amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005; 28: 66-71
21. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: A meta-analysis of randomised controlled trials. Am J Psychiat 2002; 159: 180-190
22. Lewis SW, Barnes TR, Davies L, Murray R et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715-723
23. Lewis SW, Davies L, Jones PB et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006; 10: 1-182
24. Matthiason P, Erlandsson K, Costa D et al. Amisulpride augmentation of clozapine and striatal dopamine D2 receptor binding potential. A 123-I-IBZM study. Schizophrenia Research 2003; 53 (S3): 208
25. Matthiasson P, Costa DC, Erlandsson K et al. Increased dopamine D2 receptor binding in the basal ganglia after augmenting clozapine treatment with amisulpride. An 123-I-IBZM SPECT-study. J Psychopharmacol 2000; 14S: A57
26. Moeller HJ. Amisulpride: a review of its efficacy in schizophrenia. Acta Psychiat Scand Suppl 2000; 400: 17-22
27. Molina V, Sanz J, Sarramea F, Palomo T. Marked hypofrontality in clozapine-responsive patients. Pharmacopsychiatry 2007; 40: 157-162
28. Müller MJ, Regenbogen B, Sachse J et al. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Pharmacopsychiatry 2006; 39: 41-46
29. Munro J, Matthiasson P, Osborne S et al. Amisulpride augmentation of clozapine: an open, non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004; 110: 241-242
30. Pessina A, Turlizzi E, Bonomi A et al. In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Pharmacopsychiatry 2006; 39: 20-22
31. Procopio M. Sulpiride augmentation on schizophrenia. Br J Psychiatry 1998; 2: 449-450
32. Reznik I, Yavin I, Stryjer R, Spivak B et al. Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry 2004; 37: 52-56
33. Saletu B, Grunberger J, Linzmayer L, Anderer P. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry. Pharmacopsychiatry 1987; 20: 12-27
34. Shiloh R, Zemishlany Z, Aizenberg D et al. Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study. Eur Psychiatry 1997; 12: 152-155
35. Shiloh R, Zemishlany Z, Aizenberg D et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiat 1997; 171: 569-573
36. Stubbs JH, Haw CM, Staley CJ et al. Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine. Acta Psychiatr Scand 2000; 102: 390-393
37. Zink M, Dressing H. Augmentation of clozapine with atypical antipsychotic substances. Current Psychiatry Reviews 2005; 1: 165-172
38. Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004; 19: 56-58
39. Zink M, Knopf U, Henn FA, Thome J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia - case reports and review of the literature. Pharmacopsychiatry 2004; 37: 26-31
40. Zink M, Knopf U, Mase E, Kuwilsky A, Deuschle M. Duloxetine treatment of major depressive episodes in the course of psychotic disorders. Pharmacopsychiatry 2006; 39: 109-111